UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 26, 2004

 

VERTEX PHARMACEUTICALS INCORPORATED
(Exact name of registrant as specified in its charter)

 

MASSACHUSETTS

 

000-19319

 

04-3039129

(State or other jurisdiction
of incorporation)

 

(Commission File Number)

 

(I.R.S. Employer
Identification No.)

 

 

 

 

 

130 Waverly Street
Cambridge, Massachusetts 02139

(Address of principal executive offices) (Zip Code)

 

(617) 444-6100

Registrant’s telephone number, including area code:

 

 

 


 

Item 12. Disclosure of Results of Operations and Financial Condition.

 

On July 26, 2004, Vertex Pharmaceuticals Incorporated issued a press release to report the company’s financial results for the quarter ended June 30, 2004. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

 

The information in this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

VERTEX PHARMACEUTICALS INCORPORATED
(REGISTRANT)

 

 

 

 

DATE: July 26, 2004

By:

/s/   IAN F. SMITH

 

 

 

Ian F. Smith

 

 

 

Senior Vice President and Chief Financial Officer

 

 

 

EXHIBIT INDEX

 

The following exhibits are filed as part of this current report on Form 8-K:

 

Exhibit
No.

 

Description

99.1

 

Press Release of Vertex Pharmaceuticals Incorporated dated July 26, 2004 entitled “Vertex Pharmaceuticals Reports Second Quarter 2004 Financial Results and Provides Clinical Update.”

 

2